NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?
Ionis Pharmaceuticals (IONS) is under renewed scrutiny after reporting that its late stage CARDIO TTRansform trial for eplontersen with AstraZeneca did not meet the primary efficacy endpoint, triggering a sharp share price reaction and a shareholder investigation.
See our latest analysis for Ionis Pharmaceuticals.
The eplontersen trial failure and shareholder investigation come after a sharp shift in momentum for Ionis Pharmaceuticals, with the share price down 26.10% over 30 days and 29.02%...